Canaccord Genuity analyst Cecilia Furlong maintained a Buy rating on Staar Surgical Company (NASDAQ:STAA) on Thursday, setting a price target of $70, which is approximately 16.74% above the present share price of $59.96.
Furlong expects Staar Surgical Company to post earnings per share (EPS) of $0.00 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Staar Surgical Company, with an average price target of $61.5.
The analysts price targets range from a high of $70 to a low of $55.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $35.19 million and a net profit of -$1.14 million. The company's market cap is $2.81 billion.
According to TipRanks.com, Canaccord Genuity analyst Cecilia Furlong is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 7.3% and a 66.67% success rate.
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.